1Razzouk BI, Estey E, Pounds S,et al. Impact of age on outcome Ofpediatric acute myeloid leukemia: a report from 2 institutions [ J ]. Cancer,2006,106 (11) : 2495-2502.
4Rubnitz JE, Raimondi SC, Halbert AR,et al. Characteristics and outcome of t( 8 ;21 )-positive childhood acute myeloid leukemia: a single institution's experience [ J ]. Leukemia,2002,16 : 2072 -2077.
5Hann IM ,Webb DK, Gibzon BE ,et al. MRC trials in childhood acute myeloid leukaemia [ J ]. Ann Hematol, 2004,83 ( Supple 1 ) : S108- 112.
6Creutzig U, Reinhardt D, Zimmennann M. Prognostic Relevance of Risk Groups in the Pediatric AML-BFM Trials 93 and 98 [J]. Ann Hematol,2004,83( Supple 1 ) :S112-115.
7Zwaan CM, Meshinchi S, Radich JP. FLT3 internal tandem duplication in 234 children with acute myeloid leukemia:prognostic significance and relation to cellular drug resistance [ J ]. Blood,2003,102 (7) :2387-2394.
8Boissel N, Leroy H, Brethon B, et al. Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML) [ J ]. Leukemia, 2006,20 ( 6 ) : 965- 970.
9Steinbach D, Schramm A, Eggert A, et al. Identification of a set of seven genes for the monitoring of minimal residual disease in pediatric acute myeloid leukemia [ J].Clin Cancer Res, 20061 12(8): 2434-2441.
10Langebrake C, Creutzig U, Dworzak Met al. Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry : the MRD-AML-BFM Study Group [ J].J Clin Oncol ,2006,24:3686-3692.
